Home Companies Catalysts Deep Dives
Winrevair sotatercept-csrk APPROVED
Drug Profile
ModalityFc-fusion
RouteSC
Therapy AreaCVRM
Launch2024-03-26
US LOE2037-03-01
Peak Sales Est$7000M
Formulations[{"id":"winrevair-sc","route":"SC","device":"Pre-filled syringe","setting":"PATIENT_SELF","frequency
Companies
MRK (ORIGINATOR)100%
Mechanism: ActRIIA-Fc fusion
Expert: Activin receptor type IIA-Fc fusion protein trapping TGF-β ligands
Everyday: Blocks proteins that cause blood vessel thickening in PAH
Targets: ["ACTIVIN"]
Revenue History
PeriodRevenue ($M)
2024$419M
2025$1,400M
Q2 2024$70M
Q3 2024$149M
Q4 2024$200M
Q1 2025$280M
Q2 2025$320M
Q3 2025$380M
Q4 2025$420M
Programs (2)
IndicationStageKey StudyRegional Status
PAHAPPROVEDSTELLAR[{"stage":"APPROVED","region":"US","approval_date":"2024-03-26"}]
PH-LHDPHASE3ZENITH[]
Upcoming Catalysts (1)
Winrevair - PAH - Label Expansion Data 2026
Notes
First-in-class activin signaling inhibitor for PAH. Blockbuster launch trajectory. Acquired via Acceleron.
Data from Supabase · Updated 2026-03-24